Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer

Cancer

Volumn 113, Issue 7, 2008, Pages 1521-1526

  Phipps, Amanda I ^a,b   Malone, Kathleen E ^a,b   Porter, Peggy L ^a,c   Daling, Janet R ^a,b   Li, Christopher I ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Breastfeeding; HER 2; Luminal; Menarche; Parity; Postmenopausal; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

AGED; ANAMNESIS; ARTICLE; BREAST FEEDING; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; METABOLISM; MIDDLE AGED; NEOPLASM; PARITY; POSTMENOPAUSE; PREGNANCY; RISK; RISK FACTOR;

AGED; BREAST FEEDING; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PARITY; POSTMENOPAUSE; PREGNANCY; RECEPTOR, ERBB-2; REPRODUCTIVE HISTORY; RISK FACTORS;

EID: 54049127751     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23786     Document Type: Article

References (23)

1. Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
2. Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. (Pubitemid 32878711)
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-8423. (Pubitemid 36842560)
4. Carey L, Perou C, Livasy C, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502. (Pubitemid 43854964)
5. Nielsen T, Hsu F, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374. (Pubitemid 39100473)
6. Carey L, Dees E, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334. (Pubitemid 46698581)
7. Bauer K, Brown M, Cress R, Parise C, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-1728. (Pubitemid 46668532)
8. Yang X, Sherman M, Rimm D, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007;16:439-443. (Pubitemid 46548646)
9. Lakhani S, Van De Vijver M, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310-2318. (Pubitemid 34441658)
10. Foulkes W, Stefansson I, Chappuis P, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485. (Pubitemid 37279334)
11. Kelsey J, Gammon MD, John E. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15:36-47. (Pubitemid 23269069)
12. Huang W, Newman B, Millikan R, Schell M, Hulka B, Moorman P. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000;151:703-714. (Pubitemid 30463592)
13. Potter J, Cerhan J, Sellers T, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev. 1995;4:319-326.
14. Rosenberg L, Einarsdottir K, Friman E, et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006; 15:2482-2488. (Pubitemid 46048309)
15. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8:R43.
16. Li C, Malone K, Porter P, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289:3254-3263. (Pubitemid 37430078)
17. Li C, Malone K, Porter P, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarker Prev. 2008;17:43-50. (Pubitemid 351196272)
18. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc. 1978;73:40-46.
19. Begg C, Gray R. Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika. 1984;71:11-18.
20. Ursin G, Bernstein L, Lord SJ, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer. 2005;93:364-371. (Pubitemid 43080039)
21. Nichols HB, Trentham-Dietz A, Love RR, et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev. 2005;14:41-47. (Pubitemid 40165281)
22. Tjonneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer. 2004;100:2328-2337. (Pubitemid 38657879)
23. Millikan R, Newman B, Tse C, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123-139. (Pubitemid 351538762)